Corcept CFO trades 40,000 shares after option exercise

Corcept Therapeutics Chief Financial Officer Atabak Mokari reported option exercises and share sales in the company’s common stock.

Rhea-AI Filing Summary

Corcept Therapeutics Chief Financial Officer Atabak Mokari reported option exercises and share sales in the company’s common stock. On July 15, 2026, he exercised stock options for a total of 40,000 shares at exercise prices of $23.0600 and $19.2600 per share, then sold 40,000 shares in open-market transactions at weighted average prices between $86.7760 and $89.4282 per share, with actual sale prices ranging from $86.20 to $89.43. The sales were made under a Rule 10b5-1 trading plan adopted on December 12, 2025, and the options exercised were fully exercisable.

Insider Trade Summary 10b5-1

Exercise and Sale: 40,000 shares ($2.65M approx. pre-tax spread)

Exercise and Sale 8 txns

Insider Mokari Atabak

Role Chief Financial Officer

Sold 40,000 shs ($3.51M)

Approx. gross sale proceeds $3.51M

Approx. exercise cost $862K

Approx. pre-tax spread $2.65M

Type	Security	Shares	Price	Value
Exercise	Stock option (right to buy) F7	15,833	$0.00	$0.00
Exercise	Stock option (right to buy) F7	24,167	$0.00	$0.00
Exercise	Common Stock F1	15,833	$19.26	$305K
Exercise	Common Stock F1	24,167	$23.06	$557K
Sale	Common Stock F2, F3, F1	7,919	$86.776	$687K
Sale	Common Stock F2, F4, F1	28,460	$87.8863	$2.50M
Sale	Common Stock F2, F5, F1	3,520	$88.3016	$311K
Sale	Common Stock F2, F6, F1	101	$89.4282	$9K

Holdings After Transaction: Stock option (right to buy) — 180,000 contracts (Direct); Common Stock — 16,130 shares (Direct)

Footnotes (7)

1. F1. Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
2. F2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 12, 2025 in effect at the time of this transaction.
3. F3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $86.20 to $87.19 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
4. F4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $87.23 to $88.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
5. F5. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $88.24 to $89.07 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
6. F6. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $89.25 to $89.43 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
7. F7. Fully exercisable.

Key Figures

Shares sold: 40000 shares Shares acquired via option exercise: 40000 shares Option exercise price: $23.0600 per share +3 more

6 metrics

Shares sold 40000 shares Total common shares sold in open-market transactions on 2026-07-15

Shares acquired via option exercise 40000 shares Total common shares received from stock option exercises on 2026-07-15

Option exercise price $23.0600 per share Exercise price for 24167 stock options converted into common stock

Option exercise price $19.2600 per share Exercise price for 15833 stock options converted into common stock

Sale price range $86.20–$89.43 per share Actual sale price range across reported sales, per weighted-average price footnotes

10b5-1 plan adoption date December 12, 2025 Date the CFO adopted the Rule 10b5-1 trading plan covering these sales

Key Terms

10b5-1 plan, weighted average sale price, restricted stock awards, Stock option (right to buy)

4 terms

10b5-1 plan regulatory

"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person..."

A 10b5-1 plan is a pre-arranged strategy that allows company insiders to buy or sell their shares at predetermined times and prices, even while they are aware of confidential information. It acts like a scheduled appointment for trading, helping ensure transactions happen transparently and legally, which can reassure investors that trades are not based on insider knowledge.

weighted average sale price financial

"Represents the weighted average sale price for the entire number of shares sold..."

restricted stock awards financial

"Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person..."

Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

Stock option (right to buy) financial

"Security title reported as Stock option (right to buy) with underlying common shares"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transactions did Corcept Therapeutics (CORT) CFO Atabak Mokari report?

Atabak Mokari reported exercising stock options for 40,000 Corcept shares and selling 40,000 common shares on July 15, 2026. The activity combined option exercises at preset strike prices with open-market sales executed under a pre-arranged Rule 10b5-1 trading plan.

How many Corcept (CORT) shares did the CFO sell and at what prices?

Mokari sold 40,000 Corcept common shares in multiple open-market transactions. Weighted average sale prices were $86.7760, $87.8863, $88.3016, and $89.4282 per share, with actual sale prices across all trades ranging from $86.20 to $89.43 per share.

What stock options did the Corcept (CORT) CFO exercise?

He exercised options covering 24,167 shares at $23.0600 per share and 15,833 shares at $19.2600 per share, for a total of 40,000 shares. Footnotes state these stock options were fully exercisable at the time of the transactions.

Were Mokari’s Corcept (CORT) trades made under a Rule 10b5-1 plan?

Yes. A footnote explains the reported sales were made pursuant to a Rule 10b5-1 trading plan adopted by Atabak Mokari on December 12, 2025. The filing’s 10b5-1 checkbox is also marked, indicating plan-based transactions.

Do Mokari’s Corcept (CORT) holdings include unvested restricted stock awards?

Reported holdings include shares underlying unvested restricted stock awards: 200 shares from a September 2, 2025 grant, 178 from December 1, 2025, 397 from March 2, 2026, and 634 from June 1, 2026. Each award vests 100% on its one-year anniversary if conditions are met.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 06:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mokari Atabak

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CALIFORNIA 94065

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/15/2026		M		15,833	A	$19.26	31,963(1)	D
Common Stock	07/15/2026		M		24,167	A	$23.06	56,130(1)	D
Common Stock	07/15/2026		S(2)		7,919	D	$86.776(3)	48,211(1)	D
Common Stock	07/15/2026		S(2)		28,460	D	$87.8863(4)	19,751(1)	D
Common Stock	07/15/2026		S(2)		3,520	D	$88.3016(5)	16,231(1)	D
Common Stock	07/15/2026		S(2)		101	D	$89.4282(6)	16,130(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$19.26	07/15/2026		M			15,833	(7)	02/02/2032	Common Stock	15,833	$0.00	4,167	D
Stock option (right to buy)	$23.06	07/15/2026		M			24,167	(7)	02/13/2033	Common Stock	24,167	$0.00	175,833	D

Explanation of Responses:

1. Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 12, 2025 in effect at the time of this transaction.

3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $86.20 to $87.19 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $87.23 to $88.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

5. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $88.24 to $89.07 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

6. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $89.25 to $89.43 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

7. Fully exercisable.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Atabak Mokari	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)